

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai Henlius Biotech, Inc.

上海復宏漢霖生物技術股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 2696)

INSIDE INFORMATION ANNOUNCEMENT

ISSUANCE OF THE FILING NOTICE BY THE CSRC FOR THE H SHARE FULL CIRCULATION BY THE COMPANY

This announcement is made by Shanghai Henlius Biotech, Inc. (the “**Company**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to the announcements of the Company dated 24 March 2025 and 9 June 2025 (the “**Announcements**”) in relation to the consideration and approval of the resolution on the proposed implementation of the H Share Full Circulation by the Board, as well as the acceptance by the CSRC of the filing application submitted by the Company in relation to the proposed implementation of the H Share Full Circulation. Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the Announcements.

The Board is pleased to announce that, the Company has recently received the Notification of Filing on the “Full Circulation” of Domestic Unlisted Shares of Shanghai Henlius Biotech, Inc. (《關於上海復宏漢霖生物技術股份有限公司境內未上市股份「全流通」備案通知書》) (the “**Filing Notice**”) issued by the CSRC. Pursuant to the Filing Notice, the filing by the Company with the CSRC in relation to the implementation of the H Share Full Circulation for an aggregate of 182,645,856 Unlisted Shares held by certain shareholders of the Company has been completed. If the Company fails to complete the Conversion and Listing of the H Share Full Circulation within 12 months from the date of issuance of the Filing Notice, an updated filing with the CRSC will be required if the Company intends to proceed with the Conversion and Listing. The Company will make further announcement(s) on the progress of the H Share Full Circulation and the Conversion and Listing in accordance with the requirements of the Inside Information Provisions and/or the Listing Rules.

The H Share Full Circulation and the Conversion and Listing are subject to relevant procedures as required by the Stock Exchange and other regulatory authorities. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

On behalf of the Board
Shanghai Henlius Biotech, Inc.
Wenjie Zhang
Chairman

Hong Kong, 16 January 2026

As at the date of this announcement, the board of directors of the Company comprises Mr. Wenjie Zhang as the chairman and non-executive director, Dr. Jun Zhu as the executive director, Mr. Qiyu Chen, Mr. Yuqing Chen, Ms. Xiaohui Guan, Dr. Yi Liu and Dr. Xingli Wang as the non-executive directors, and Mr. Tak Young So, Dr. Lik Yuen Chan, Dr. Ruilin Song and Mr. Yihao Zhang as the independent non-executive directors.